Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain McNeish

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Cancers|January 21, 2023
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian CancerSudha Sundar, Andy Nordin, Jo Morrison, et al.
Cell Reports|July 21, 2021
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STINGMarine Bruand, David Barras, Marco Mina, et al.
The Lancet. Oncology|July 28, 2022
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroupIgnace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, et al.
Nature Communications|February 16, 2017
Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activityJuan R Hernandez-Fernaud, Elena Ruengeler, Andrea Casazza, et al.
Nature Communications|October 26, 2022
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancerFilipe Correia Martins, Dominique-Laurent Couturier, Ines de Santiago, et al.
Gynecologic Oncology|May 24, 2019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 8, 2021
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448Paul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 24, 2020
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]Paul A Cohen, Aime Powell, Steffen Böhm, et al.
Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Cancers|January 21, 2023
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian CancerSudha Sundar, Andy Nordin, Jo Morrison, et al.
Cell Reports|July 21, 2021
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STINGMarine Bruand, David Barras, Marco Mina, et al.
The Lancet. Oncology|July 28, 2022
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroupIgnace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, et al.
Nature Communications|February 16, 2017
Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activityJuan R Hernandez-Fernaud, Elena Ruengeler, Andrea Casazza, et al.
Nature Communications|October 26, 2022
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancerFilipe Correia Martins, Dominique-Laurent Couturier, Ines de Santiago, et al.
Gynecologic Oncology|May 24, 2019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 8, 2021
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448Paul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 24, 2020
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]Paul A Cohen, Aime Powell, Steffen Böhm, et al.
Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Pageof 7